Krishna Institute of Medical Sciences share price today

Krishna Institute of Medical Sciences Ltd's share price was ₹723.00 at the close on 6 November 2026. It has been rising for 25 weeks. That is 1.3% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 7 weeks running.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Krishna Institute of Medical Sciences Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹582 and ₹851, and at that close it sat 52% of the way up from that low.

Over the last 5.3 years the share price moved +255% while the NIFTY 500 moved +61%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹1,180 crore, +35.3% on a year earlier.

   Why: Revenue rose because more patients came to its hospitals. Inpatient visits and outpatient visits both grew from a year earlier.

   Next results: check whether the new insurance approvals bring more patients to the new hospitals.

   From the earnings call on 4 Aug 2026.

3. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 14.3% to 15% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Krishna Institute of Medical Sciences reported revenue of ₹1,180 crore, up 35.3% from ₹872 crore a year earlier, and a profit of ₹37.0 crore, down 56.5% from ₹85.0 crore.

Krishna Institute of Medical Sciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Krishna Institute of Medical Sciences' management discussed these results on a call held on 4 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Krishna Institute of Medical Sciences closed at ₹723.00 on 6 November 2026, down 0.7% from ₹728.10 a year earlier (7 November 2025) and up 211.6% over five years. Its highest weekly close since July 2021 was ₹850.65 on 3 July 2026.

Krishna Institute of Medical Sciences share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

286 weekly closes from 2 July 2021 to 6 November 2026.

6 Nov 2026: Krishna Institute of Medical Sciences closed at ₹723.00, up 3.0% on the week and up 2.5% on the month. 4 Aug 2026: Krishna Institute of Medical Sciences held its results call for April to June 2026. Management guided: Current hospitals prioritized for stabilization over the next two quarters; Nashik commissioning planned in three to four months, Electronic City break-even within one to two quarters, and Bangalore full-year operating profit neutrality.

Earlier

• Results for April to June 2026: Revenue up 35.3% and profit down 56.5% on a year earlier.
• 13 Sep 2024: Share split: face value cut from ₹10 to ₹2 a share (ex-date).

Krishna Institute of Medical Sciences has paid no dividend on the NSE since its first NSE close in our records (2 July 2021), the start of the period we checked.

No. Krishna Institute of Medical Sciences Ltd paid out 0% of its profit as dividends in each of its last 11 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 7 November 2026.

On the call for April to June 2026, held on 4 August 2026, Krishna Institute of Medical Sciences' management guided: Current hospitals prioritized for stabilization over the next two quarters; Nashik commissioning planned in three to four months, Electronic City break-even within one to two quarters, and Bangalore full-year operating profit neutrality.

“We are not looking at opening any new geography.”Dr. Abhinay Bollineni, on the call for April to June 2026

What management guided

• Key insurer empanelments for Nashik, Thane and both Bangalore assets planned by end-August or mid-September, with the majority complete by year-end; Bangalore ARPOB to settle around ₹82,000-85,000 after empanelment.
• Kerala operating margin to remain single-digit through FY27, move to mid-teens next year, and stabilize around 20-22% over the following two to three years.
• Kondapur revenue potential around ₹100 crore monthly or ₹1,200 crore annually over four to five years; modelled margin 30-32% at scale.
• ARPOB growth of 4-5% is a reasonable ongoing assumption; current hospitals to reach 65-70% occupancy by FY30 without additional beds, with Telangana operating margin returning to 30-35% as capacity matures.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 4 August 2026.

When Krishna Institute of Medical Sciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Electronic City and the Bangalore cluster: check whether the remaining drag narrows as monthly break-even converts into reported-quarter progress.

Krishna Institute of Medical Sciences is on one of our India lists: Small & mid cap stocks.

Krishna Institute of Medical Sciences Ltd earned ₹37.0 Cr of net profit in the Jun 2026 quarter, −56.5% on the same quarter a year earlier. Full-year FY26 profit was ₹242 Cr. Over 10 years profit has grown 24.1% a year on average. That is 3.1% of the quarter's revenue. The same quarter a year earlier earned ₹85.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹242 Cr (−41.7% on the year before).

Why profit moved: revenue changed +35.3% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −52.4% and revenue +30.8%. Profit is growing slower than sales: rising costs are taking part of the growth.

Krishna Institute of Medical Sciences Ltd reported ₹1,180 Cr of revenue in the Jun 2026 quarter, +35.3% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 22.5% a year on average. The last full year, FY26, came in at ₹3,905 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹4,214 Cr.

FY26 revenue was ₹3,905 Cr, +28.7% on the year before.

Recent pace: the last four quarters grew +30.8% on average, against 22.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +31.0%, against +27.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −52.0%, against −25.0% a year (rolling over).

Krishna Institute of Medical Sciences Ltd's operating margin was 19.0% in the Jun 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Across 11 years it has been between 9.0% and 32.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −3.2 percentage points on the year while gross margin changed +0.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 163% of Krishna Institute of Medical Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹511 Cr of operating cash against ₹242 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹2,037 Cr of spending on assets, free cash was −₹1,526 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 163% of profit came in as cash: the cash cycle got 158 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 7.7× depreciation over three years. The next section checks what that spending is building.

Krishna Institute of Medical Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 52 days in FY26, up from −106 days in FY21. It spent ₹4,680 Cr on assets over the last 3 years. Customers take 52 days to pay, and stock sits for 44 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹3,905 Cr, each day of that cycle ties up about ₹10.7 Cr, so roughly ₹556 Cr is tied up in the business at any time.

FY26: customers took 52 days to pay and stock sat for 44 days, about 1.4 months of sales sitting as stock, for a full cycle of 52 days, longer than FY21's −106.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 44 days. Customers pay about 52 days after that. Suppliers are paid at 146 days. Together that makes the 52-day cycle.

Spending on assets: ₹4,680 Cr over the last 3 years, against ₹607 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹606 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Krishna Institute of Medical Sciences Ltd's P/E is 145.2×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 52.7×, over 5.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹5.05.

Why the multiple is where it is: over the past year earnings per share moved −37.3% while the price moved −0.7%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +25.5% a year; about −0.3% a year came from earnings growth and about +25.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 27% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Krishna Institute of Medical Sciences Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −52.0% in the latest quarter, against +22.8% at its best in 12 quarters, with ROCE falling at 10.0%. This is based on 8 quarters of 4 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

October to December 2025 revenue crossed ₹1,000 Cr milestone (+26.9% on a year earlier), operating profit ₹204 Cr (20.4% margin), ARPOB +20.5% on a year earlier. BUT profit collapsed -39.9% on a year earlier to ₹52 Cr due to new hospital drag. New 350-bed Bangalore Electronic City hospital started Dec 2025, breakeven 12+ months away.

Regulatory and governance record

No fraud or controversies. Promoter pledge activity (Jun 2024, ~₹330 Cr) partially revoked by Sep 2024. Not a structural concern but flagged.

Checked 22 March 2026.

Krishna Institute of Medical Sciences Ltd earned a ROCE of 10% in FY26. That is up from a low of 5% in FY19. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 6.2% net margin and 0.51× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 6.2% net margin × 0.51× asset turnover × 3.42× leverage (assets divided by equity) ≈ 10.8% on equity. The margin does its share; borrowing is a big part of it.

The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 27% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Krishna Institute of Medical Sciences Ltd had ₹4,253 Cr of borrowings against ₹2,247 Cr of equity in FY26, so its debt is 1.89× its equity. Its operating profit is 4 times its interest bill. Over 5 years borrowings went from ₹316 Cr to ₹4,253 Cr. Over the last 3 of those years it spent ₹4,680 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

Part of the spending on assets is being paid for with borrowed money.

The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 27% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.

Promoters cut their stake in Krishna Institute of Medical Sciences Ltd by 6.2 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 32.6% of the company. Domestic institutions moved +0.9 points over the same period, to 33.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −6.2 points over 8 quarters, to 32.6%; Domestic institutions: +0.9 points over 8 quarters, to 33.2%; Foreign institutions: −0.8 points over 8 quarters, to 15.0%.

Why the owners changed: promoters drove it (−6.2 points), with the other side taken by domestic institutions (+0.9 points). They reduced their stake.

For Krishna Institute of Medical Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

34.5 out of 100, rank 16 of 20 in Hospitals, with 78% of the evidence available.

Krishna Institute of Medical Sciences Ltd scores 34.5 out of 100 against the 20 companies it is compared with in Hospitals, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 10 + 9.1 + 6.1 + 9.3 = 34.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Krishna Institute of Medical Sciences ranks 16 of 20 Hospitals companies on the 4-Factor Sector Score, with 34.5 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Hospitals, all 20 compared on one page.

Krishna Institute of Medical Sciences is the 8th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Fortis Healthcare, Narayana Hrudayalaya and Global Health. Just below it: Rainbow Childrens Medicare, Yatharth Hospital & Trauma Care Services and Healthcare Global Enterprises.

Hospitals companies close in size

5. Fortis Healthcare Ltd ₹57,992 crore
6. Narayana Hrudayalaya Ltd ₹35,154 crore
7. Global Health Ltd ₹34,156 crore
8. Krishna Institute of Medical Sciences Ltd ₹29,476 crore
9. Rainbow Childrens Medicare Ltd ₹12,378 crore
10. Yatharth Hospital & Trauma Care Services Ltd ₹9,902 crore
11. Healthcare Global Enterprises Ltd ₹8,742 crore

All 20 Hospitals companies, largest first

Companies close in size in other industries

281. Inventurus Knowledge Solutions Ltd ₹30,163 crore · IT Enabled Services/Business Process Outsourcing
282. Angel One Ltd ₹29,847 crore · Finance - Capital Markets - Brokers
283. Krishna Institute of Medical Sciences Ltd ₹29,476 crore
284. Cochin Shipyard Ltd ₹29,312 crore · Ship - Docks/Breaking/Repairs
285. Syrma SGS Technology Ltd ₹29,262 crore · Consumer Electronics - EMS

Sector Alpha, written by code from the published numbers. Data as of 6 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.